Short Interest in Decoy Therapeutics (NASDAQ:DCOY) Declines By 51.5%

Decoy Therapeutics (NASDAQ:DCOY) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 11,279 shares, a decrease of 51.5% from the April 15th total of 23,252 shares. Based on an average daily trading volume, of 13,202 shares, the days-to-cover ratio is presently 0.9 days. Currently, 2.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Decoy Therapeutics in a research report on Friday, January 23rd. They set a “buy” rating and a $30.00 target price on the stock. Wall Street Zen upgraded shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Decoy Therapeutics presently has an average rating of “Hold” and an average target price of $30.00.

Decoy Therapeutics Price Performance

DCOY stock opened at $4.41 on Monday. The firm has a 50 day simple moving average of $6.36. The firm has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.04 and a beta of 0.38. Decoy Therapeutics has a 12 month low of $4.32 and a 12 month high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last released its quarterly earnings results on Friday, May 8th. The company reported ($4.18) EPS for the quarter. Sell-side analysts expect that Decoy Therapeutics will post -12.97 EPS for the current year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.